drugset
drugset / Trial / NCT03018665

A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

NCT03018665 ↗

Phase 4 Unknown 200 enrolled The First Hospital of Jilin University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effect of GLP-1 receptor agonist on inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese

Timeline

Start
2017-02
Primary completion
2021-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator BIAsp 30 Unknown — Subcutaneous
Subject Exenatide Peptide 10 ug Subcutaneous
Background Metformin Small molecule 0.85 g Oral

Indications

type 2 diabetes mellitus